Lantern Pharma (Lantern Pharma) Cyclically Adjusted PS Ratio : (As of Jun. 08, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma Cyclically Adjusted PS Ratio?

Lantern Pharma does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation

Lantern Pharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Lantern Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantern Pharma Cyclically Adjusted PS Ratio Chart

Lantern Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cyclically Adjusted PS Ratio

Get a 7-Day Free Trial

Lantern Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lantern Pharma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Lantern Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantern Pharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's Cyclically Adjusted PS Ratio falls into.

Lantern Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lantern Pharma does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Lantern Pharma (NAS:LTRN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

Lantern Pharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantern Pharma (Lantern Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Cyclically Adjusted PS Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201

Website

https://www.lanternpharma.com

Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Executives

Leslie W. Kreis	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l.	10 percent owner	40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini	director	1223 FOXGLOVE LANE, WEST CHESTER PA 19380